Clinical Trial Update: A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) [Phase 3]

View source ↗

Summary

Phase 3 trial update for Lanadelumab in teenagers and adults with non-histaminergic angioedema with normal C1-inhibitor has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioedema

Drugs mentioned

• Lanadelumab (lanadelumab)

Snippet

Sponsor: Takeda | Conditions: Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2023-12-27